Browsing by Author "Ozguroglu, Mustafa"
Now showing items 1-3 of 3
-
External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC): Results From the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database
Yekeduz, Emre; Karakaya, Serdar; Erturk, Ismail; Tural, Deniz; Ucar, Gokhan; Oztas, Nihan Senturk; Ozguroglu, Mustafa; Kucukarda, Ahmet; Sever, Ozlem Nuray; Kilickap, Saadettin; Oksuzoglu, Berna; Demirci, Umut; Arikan, Nuriye (Elsevier, 2022)Background: A novel prognostic model was recommended for patients with metastatic RCC (mRCC) by the International mRCC Database Consortium (IMDC). In this study, we aimed to externally validate a novel risk model for the ... -
Patient-reported outcomes (PROs) of cemiplimab vs chemotherapy in advanced non-small cell lung cancer (aNSCLC): EMPOWER-lung 1 histology subgroups
Sezer, A.; Kilickap, Saadettin; Gumus, M; Bondarenko, Igor; Ozguroglu, Mustafa; Gogishvili, Miranda; He, X.; Gullo, Guiseppe; Rietschel, Petra; Quek, Ruben (ELSEVIER, 2022)Patient-reported outcomes (PROs) of cemiplimab vs chemotherapy in advanced non-small cell lung cancer (aNSCLC): EMPOWER-Lung 1 histology subgroups -
Patient-reported outcomes of cemiplimab versus chemotherapy in advanced NSCLC: PD-L1 level subgroups in EMPOWER-lung 1
Sezer, Ahmet; Gumus, Mahmut; Bondarenko, Igor N; Ozguroglu, Mustafa; Gogishvili, Miranda; He, X.; Gullo, Guiseppe; Rietschel, Petra; Quek, Ruben Gw (Elsevier Science, 2022)Patient-reported outcomes of cemiplimab versus chemotherapy in advanced NSCLC: PD-L1 level subgroups in empower-lung 1
